Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing

Table 3 Morbidity (measured by TBscore), 6-month all cause mortality and lost-to-follow up stratified by baseline results of LAM in HIV-infected (or test refused) patients^a

	All HIV-infected n/N (%)	LAM strip positive n/N (%)	LAM strip negative n/N (%)	P-value
6-month mortality (N = 393)^b	49/393 (13)	9/32 (25)	40/361 (11)	0.021
TB culture-positive only (N = 123)^b		6/17 (35)	15/106 (14)	0.032
Lost-to-follow up	190/583 (33)	38 (54)	152 (30)	<0.001
Culture-positive (N = 58)		24/41 (59)	34/140 (24)	<0.001
TBscore at enrolment
Culture-positive (N = 181)	6 (4-7.5)	7 (6-8)	5 (4-7)	0.025

^a14 HIV-infected and test refused patients with no reference standard result (see Fig. 1) excluded from the analyses of index test diagnostic accuracy are included in this analysis of morbidity and mortality. Thus a total of 583 patients are included in this table’s analysis
^bOf the 583 HIV-infected patients with a LAM result, 190 were lost-to-follow-up at 6-months. Of the 393 patients with complete 6-month follow-up data, 123 were culture-positive TB

ISSN: 1471-2334